GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Comera Life Sciences Holdings CMRA · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

0.00%

Close of 4 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2023

Revenue

$1.0m

FY2020FY2023

Net income

−$9.0m

FY2020FY2023

Free cash flow

−$6.8m

FY2020FY2023

Shareholders' equity

—

FY2020FY2023

Income statement

Fiscal years

FY2023FY2022FY2021FY2020
Revenue$1.0m$633,102$319,832$442,919
Research and development$1.4m$1.7m$1.8m$1.3m
Operating income−$9.1m−$12.0m−$5.5m−$2.1m
Net income−$9.0m−$24.0m−$5.3m−$2.1m
Diluted earnings per share-0.39-2.30-0.28-0.71

Balance sheet

At each fiscal year end

FY2023FY2022FY2021FY2020
Total assets—$3.7m$7.4m$545,878
Cash and short-term investments—$446,607$6.5m$155,427
Total liabilities—$10.0m$22.1m$393,963
Debt—$775,048$323,056$160,588
Shareholders' equity—−$6.2m−$14.7m$151,915
Shares outstanding23m10m19m3m

Cash flow

Fiscal years

FY2023FY2022FY2021FY2020
Cash from operations−$6.7m−$9.8m−$3.8m−$1.8m
Capital spending−$94,009−$28,607−$142,013−$12,366
Free cash flow−$6.8m−$9.8m−$3.9m−$1.8m

Latest quarters

By quarter end

Sept 2023Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022Mar 2022Dec 2021
Revenue$136,310$315,055$392,915$156,120$234,922$146,726$95,334$73,334
Operating income−$2.2m−$1.5m−$2.5m−$3.0m−$2.5m−$4.0m−$2.5m−$2.0m
Net income−$2.2m−$1.4m−$77.8m−$2.9m−$3.6m−$14.2m−$3.3m−$2.0m
Diluted earnings per share-0.09-0.06-3.36-0.28-0.35-1.36-0.32-0.11
Cash from operations−$1.0m—−$1.0m−$1.0m−$2.0m−$2.0m−$2.0m−$1.0m
Capital spending———−$28.0m————
Free cash flow———−$29.0m————
Total assets$3.1m$2.3m$3.0m$3.7m$4.9m$6.1m$5.0m$7.4m
Cash and short-term investments$1.8m$476,302$1.5m$446,607$2.7m$4.9m$3.9m$6.5m
Debt$171,596$806,688$217,500$654,746$1.1m$191,400$124,000$121,552
Shareholders' equity−$4.2m−$6.4m−$5.3m−$6.2m−$3.4m−$1.8m−$17.1m−$14.7m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue31.2%——
Operating income62.6%——
Net income61.8%——

Valuation history

At each fiscal year end

FY2023FY2022
Price to earnings-0.0—
Price to sales0.10.1

Share price return

Finished calendar years

2025202420232022
Return300%-99%-66%-86%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.